Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

Vittorio Emanuele Muccio, Elona Saraci, Milena Gilestro, Valter Gattei, Antonella Zucchetto, Monica Astolfi, Marina Ruggeri, Eleonora Marzanati, Roberto Passera, Antonio Palumbo, Mario Boccadoro, Paola Omedè

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.

Original languageEnglish
Pages (from-to)81
Number of pages90
JournalCytometry Part B - Clinical Cytometry
DOIs
Publication statusPublished - 2016

Fingerprint

Surface Antigens
Plasma Cells
Multiple Myeloma
Healthy Volunteers
Residual Neoplasm
Flow Cytometry
Plasma Cell Leukemia
Antigens
HLA Antigens
Fluorescence
Monoclonal Antibodies
Education
Cell Line
Therapeutics

Keywords

  • CD150
  • CD272
  • Multiple myeloma
  • Plasma cell immunophenotype
  • SLAM

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Pathology and Forensic Medicine

Cite this

Multiple myeloma : New surface antigens for the characterization of plasma cells in the era of novel agents. / Muccio, Vittorio Emanuele; Saraci, Elona; Gilestro, Milena; Gattei, Valter; Zucchetto, Antonella; Astolfi, Monica; Ruggeri, Marina; Marzanati, Eleonora; Passera, Roberto; Palumbo, Antonio; Boccadoro, Mario; Omedè, Paola.

In: Cytometry Part B - Clinical Cytometry, 2016, p. 81.

Research output: Contribution to journalArticle

Muccio, VE, Saraci, E, Gilestro, M, Gattei, V, Zucchetto, A, Astolfi, M, Ruggeri, M, Marzanati, E, Passera, R, Palumbo, A, Boccadoro, M & Omedè, P 2016, 'Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents', Cytometry Part B - Clinical Cytometry, pp. 81. https://doi.org/10.1002/cyto.b.21279
Muccio, Vittorio Emanuele ; Saraci, Elona ; Gilestro, Milena ; Gattei, Valter ; Zucchetto, Antonella ; Astolfi, Monica ; Ruggeri, Marina ; Marzanati, Eleonora ; Passera, Roberto ; Palumbo, Antonio ; Boccadoro, Mario ; Omedè, Paola. / Multiple myeloma : New surface antigens for the characterization of plasma cells in the era of novel agents. In: Cytometry Part B - Clinical Cytometry. 2016 ; pp. 81.
@article{49042ee87f924127a5dada5d62a76d2e,
title = "Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents",
abstract = "Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the {"}Ninth International Workshop on Leukocyte Antigens{"} was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.",
keywords = "CD150, CD272, Multiple myeloma, Plasma cell immunophenotype, SLAM",
author = "Muccio, {Vittorio Emanuele} and Elona Saraci and Milena Gilestro and Valter Gattei and Antonella Zucchetto and Monica Astolfi and Marina Ruggeri and Eleonora Marzanati and Roberto Passera and Antonio Palumbo and Mario Boccadoro and Paola Omed{\`e}",
year = "2016",
doi = "10.1002/cyto.b.21279",
language = "English",
pages = "81",
journal = "Cytometry Part B - Clinical Cytometry",
issn = "1552-4949",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Multiple myeloma

T2 - New surface antigens for the characterization of plasma cells in the era of novel agents

AU - Muccio, Vittorio Emanuele

AU - Saraci, Elona

AU - Gilestro, Milena

AU - Gattei, Valter

AU - Zucchetto, Antonella

AU - Astolfi, Monica

AU - Ruggeri, Marina

AU - Marzanati, Eleonora

AU - Passera, Roberto

AU - Palumbo, Antonio

AU - Boccadoro, Mario

AU - Omedè, Paola

PY - 2016

Y1 - 2016

N2 - Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.

AB - Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.

KW - CD150

KW - CD272

KW - Multiple myeloma

KW - Plasma cell immunophenotype

KW - SLAM

UR - http://www.scopus.com/inward/record.url?scp=84945275358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945275358&partnerID=8YFLogxK

U2 - 10.1002/cyto.b.21279

DO - 10.1002/cyto.b.21279

M3 - Article

AN - SCOPUS:84945275358

SP - 81

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

SN - 1552-4949

ER -